DEVELOPMENT AND EVALUATION OF CONTROLLED POROSITY OSMOTIC TABLETS OF CANDESARTAN CILEXETIL USING INCLUSION COMPLEX SYSTEM

ASHWIN KUMAR K; GRACE RATHNAM

doi:10.22159/ajpcr.2025v18i1.53194

Authors

ASHWIN KUMAR K Department of Pharmaceutics, C. L. Baid Metha College of Pharmacy, Chennai, Tamil Nadu, India.
GRACE RATHNAM Department of Pharmaceutics, C. L. Baid Metha College of Pharmacy, Chennai, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2025v18i1.53194

Keywords:

Candesartan cilexetil, Controlled porosity osmotic pump, Osmogen, Mannitol, Lactose monohydrate, Cellulose acetate

Abstract

Objective: This study aims to enhance the solubility of BCS Class-II drug candesartan cilexetil (CC) by forming inclusion complexation with hydroxypropyl β-cyclodextrin (CDs) and develop a controlled-release osmotic tablet for 24-h release.

Methods: Solubility of Candesartan was enhanced using hydroxypropyl β-CDs at a molar ratio1:1 and analyzed for drug content and drug release profile. Fourier transform infrared interaction studies were conducted in drug complex and excipients. Core tablets were prepared with various ratios of osmogens (mannitol: Lactose monohydrate). Pre-compression studies were performed, and cellulose acetate solution containing sorbitol as pore-forming agent was used to coat the tablet cores, achieving 3% and 5% weight gain. The core tablets were subjected to post-compression tests assessing parameters such as thickness, weight variation, hardness, friability, and drug content, while the coated tablets underwent in vitro dissolution studies. Data obtained were subjected to drug release kinetics and formulation F6 was subjected to stability studies.

Results: Characterization confirmed good flow properties, mechanical stability, and uniform drug content. Formulation F6 coated with cellulose acetate, showed 97.33% drug release at 24 h, following zero-order kinetics. Stability studies indicated that F6 remained stable for 3 months, with no notable changes in attributes such as appearance, drug content, and dissolution profile.

Conclusion: This study successfully formulated a controlled drug delivery system for CC using controlled porosity osmotic delivery suggesting its potential for further development and clinical evaluation to enhance patient compliance and therapeutic efficacy.

Downloads

Download data is not yet available.

References

Babu A, Rao MP, Vijaya Rathna J. Controlled porosity osmotic pump tablets-an overview. J Pharm Res Health Care. 2010;2(1):114-26.

Choudhary S, Subrahmanyam CV, Priyanka K. Osmotic drug delivery system of nicorandil: Design and evaluation. Int J Appl Pharm. 2024;16(3):119-28. doi: 10.22159/Ijap.2024v16i3.50298

Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens. 2000;13(1 Pt 2):18S-24. doi: 10.1016/s0895-7061(99)00250-2, PMID: 10678284

Hübner R, Högemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens. 1997 Sep 11;2(Suppl 2):S19-25. PMID: 9331000

Amer AM, Allam AN, Abdallah OY. Preparation, characterization and ex vivo-in vivo assessment of candesartan cilexetil nanocrystals via solid dispersion technique using an alkaline esterase activator carrier. Drug Dev Ind Pharm. 2019;45(7):1140-8. doi: 10.1080/03639045.2019.1600533, PMID: 30912678

Alatas F, Ratih H, Sutarna TH, Fauzi ML. The binary and ternary amorphous systems of candesartan cilexetil preparation to improve its solubility. Int J Appl Pharm. 2024;16(5):368-73. doi: 10.22159/ ijap.2024v16i5.51141

Jansook P, Kulsirachote P, Asasutjarit R, Loftsson T. Development of celecoxib eye drop solution and microsuspension: A comparative investigation of binary and ternary cyclodextrin complexes. Carbohydr Polym. 2019;225:115209. doi: 10.1016/j.carbpol.2019.115209, PMID: 31521306

Salústio PJ, Pontes P, Conduto C, Sanches I, Carvalho C, Arrais J, et al. Advanced technologies for oral controlled release: Cyclodextrins for oral controlled release. AAPS PharmSciTech. 2011;12(4):1276-92. doi: 10.1208/s12249-011-9690-2, PMID: 21948320

Todkar S, Dhole S, Umate T, Kulkarni N. Cyclodextrin in novel formulations and solubility enhancement techniques: A review. Int J Curr Pharm Res. 2024;16(2):9-18. doi: 10.22159/ijcpr.2024v16i2.4032

Cheirsilp B, Rakmai J. Inclusion complex formation of cyclodextrin

with its guest and their applications. Biol Eng Med. 2016;2(1):1-6. doi: 10.15761/BEM.1000108

Aziz GM, Al-Khedairy EB. Solubility and dissolution enhancement of candesartan cilexetil by complexation with cyclodextrin. Int J Drug Deliv Technol. 2024;14(1):257-64. doi: 10.25258/ijddt.14.1.37

Rani AP, Murthy VS, Madhavi BR. Comparative study on the preparation and characterization of inclusion complexes of BCS class II drug with cyclodextrins. Adv Res Pharm Biol. 2013;3(II):420-5.

Sravya M, Deveswaran R, Bharath S, Basavaraj BV, Madhavan V. Development of orodispersible tablets of candesartan cilexetil-β- cyclodextrin complex. J Pharm (Cairo). 2013;2013:583536. doi: 10.1155/2013/583536, PMID: 26555987

Shah M, Mehta T, Amin A. Preparation and characterization of inclusion complex of a calcium channel blocker. Int J Pharm Biomed Sci. 2011;2:1731-8.

Shirse P, Rao KS, Iqbal MM. Formulation and evaluation of cyclodextrin inclusion complex tablets of water insoluble drug-glimipiride. Int J Res Pharm Chem. 2012;2(1):222-8.

Kaushik S, Pathak K. Development and evaluation of monolithic osmotic tablet of ketoprofen: Using solid dispersion technique. Int J Pharm Pharm Sci. 2016;8(12):41-7. doi: 10.22159/ijpps.2016v8i12.11437.

Aulton ME, Taylor KM. Aulton’s Pharmaceutics: The Design and Manufacturing of Medicines. 3rd ed. London: Elsevier; 2013. p. 329, 335-53.

Ammar HO, Makram TS, Mosallam S. Effect of polymers on the physicochemical properties and biological performance of fenoprofen calcium dehydrate-triacetyl-β-cyclodextrin complex. Pharmaceutics. 2017;9(3):23. doi: 10.3390/pharmaceutics9030023, PMID: 28671624

Aparna C, Anusha M, Manisha B. Enhancement of dissolution of candesartan cilexetil. Asian J Pharm Clin Res. 2023;16(3):148-51. doi: 10.22159/Ajpcr.2023.V16i3.46626

Kar R, Mohapatra S, Bhanja S, Das D, Barik B. Formulation and in vitro characterization of xanthan gum-based sustained release matrix tablets of isosorbide-5-mononitrate. Iran J Pharm Res. 2010;9(1):13-9. PMID: 24363701

Soroush H, Ghorbani-Bidkorbeh F, Mortazavi SA, Mehramizi A. Formulation optimization and assessment of dexamethasone orally disintegrating tablets using box-Behnken design. Iran J Pharm Res. 2018;17(4):1150-63. PMID: 30568675

Alkhafaji SL, Alazawy RA, Mahood AM. Spectrophotometric determination of candesartan cilexetil and atenolol in pure and pharmaceutical forms. Int J Pharmacol Res. 2020;12(1):336-44. doi: 10.31838/ijpr/2020.12.01.059

Rane Y, Mashru R, Sankalia M, Sankalia J. Effect of hydrophilic swellable polymers on dissolution enhancement of carbamazepine solid dispersions studied using response surface methodology. AAPS PharmSciTech. 2007 Apr 6;8(2):27. doi: 10.1208/pt0802027, PMID: 17622105

Hoppe K, Sznitowska M. The effect of polysorbate 20 on solubility and stability of candesartan cilexetil in dissolution media. AAPS PharmSciTech. 2014;15(5):1116-25. doi: 10.1208/s12249-014-0109-8, PMID: 24871550

Saokham P, Muankaew C, Jansook P, Loftsson T. Solubility of cyclodextrins and drug/cyclodextrin complexes. Molecules. 2018 May 11;23(5):1161. doi: 10.3390/molecules23051161, PMID: 29751694